Effects of Cyclosporine 0.05% ophthalmic solution on diagnostic parameters of dry eye disease

Maneesha Sethi, Amarjeet Singh Bali, P. Sadhotra


Background: Dry eye is a multifactorial disease particularly prevalent in Asia for which there are several treatments. Among anti-inflammatory treatment, cyclosporine 0.05% is preferred therapy. Our study evaluated effects of cyclosporine 0.05% ophthalmic solution on the diagnostic tools of dry eye.

Material & Methods: A prospective study was carried out in ophthalmological outpatient department of ASCOMS and Hospital. Total 60 patients of dry eye disease who fulfilled the inclusion criteria were treated with cyclosporine 0.05% ophthalmic solution twice a day. The diagnostic parameters of dry eye were assessed at baseline, at month 1 and 3. Patients underwent Ocular Surface Disease Index (OSDI) score, Schirmer’s test, Tear film break up time (TBUT) .

Results: After three months, mean OSDI score was significantly improved (p < 0.001). There was significant improvement in mean Schirmer score (p < 0.001). Baseline TBUT also increased significantly (p < 0.001).

Conclusion: Cyclosporine 0.05% ophthalmic solution has significant effect on diagnostic parameters of dry eye disease.




Cyclosporine, Dry eye disease, Ocular surface disease index, Schirmer’s test

Full Text:



Stevenson W, Chauhan SK, Dana R. Dry eye disease an immune mediated ocular surface disorder. Arch Ophthal. 2012;130:90-100.

Lin PY, Tsai SY, Cheng CY. Prevalence of dry eye among an elderly chinese population in Taiwan. Ophthalmol. 2003;110:1096-101.

Lee AJ, Lee J, Saw SM. Prevalence and risk factors associated with dry eye symptoms; a population bases study in Indonesia. Br J Ophthalmol. 2002;86:1347-51.

Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision - related quality of life. Am J Ophthalmol. 2007;143:409-15.

Uchino M, Scaumberg DA. Dry eye disease: Impact on quality of life and vision. Currophthalmol Rep. 2013;1:51-7.

Schiffman R, Christianson D, Jacobson G. Reliability and validity of ocular surface disease index. Arch Ophthalmol. 2000;118:615-21.

Bhavsar AS, Bhavsar SG, Jain SM. A review on recent advances in dry eye: Pathogenesis and management. Oman J Ophthal. 2011;4:50-6.

Yayuz B, Bozdag Pehlivan S, Unlu N. An overview on dry eye treatment: approaches for cyclosporine in delivery. Scientific World J. 2012;2012:194848.

Doughty MJ, Glavin S. Efficacy of different dry eye treatment with artificial tears or ocular lubricants: a systematic review. Ophthalmic Physiol Opt. 2009;29:573-83.

Gayton JL. Etiology, Prevalence and treatment of dry eye disease. Clinophthalmol. 2009;3:405-12.

Kymionis GD, Bouzoukis DI, Diakonis VF and Siganos C. Treatment of chronic dry eye: focus on cyclosporine. Clin Ophthalmol. 2008;2:829-36.

Schultz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis. 2014;6:37-42.

The epidemiology of dry eye disease: report of the Epidemiology subcommittee of the international dry eye workshop. Ocul Surf. 2007;5:93-107.

Stonecipher KG, Torkildsen GL, OuslerIII GW. The IMPACT study: a prospective evaluation of the effects of cysclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye. Clin Ophthalmol. 2016;10:887-95.

Moon JW, Lee HJ, Shin KC. Short term effects of topical cyclosporine and viscoelastic on the ocular surfaces in patients with dry eye. Korean J Ophthalmol. 2007;21:189-94.

Chung YW, Oh TH, Chung SK. The effect of topical cyclosporine 0.05% on dry eye after cataract surgery. Korean J Ophthalmol. 2013;27:167-71.

Byun YS, Rho CR, Cho K. Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea; a prospective, multicentre open -label surveillance study. Korean J Ophthalmol. 2011;25:369-74.